Transgenic major histocompatibility complex class I antigen expressed in mouse trophoblast affects maternal immature B cells.

We have produced transgenic mice using the mouse placental lactogen type II promoter to force and restrict the expression of the mouse major histocompatibility complex (MHC) class I molecule, H-2K(b), to the placenta. We show that the transgenic MHC antigen H-2K(b) is expressed exclusively in trophoblast giant cells from Day 10.5 until the end of gestation.

Maternal B lymphocytes specific for paternal histocompatibility antigens are partially deleted during pregnancy.

Although genetically different from its mother, a mammalian fetus bearing paternal alloantigens is normally not rejected. To investigate one of the many possible mechanisms involved in this important biologic phenomenon, we analyzed the consequences of fetal alloantigen recognition on maternal B lymphocytes. We used transgenic mice expressing a unique B cell receptor with a relatively high affinity for the MHC class I molecule H-2Kk on most B lymphocytes.

Characterization of the microtubule-binding domain of microtubule-associated protein 1A and its effects on microtubule dynamics.

To determine how MAP1a interacts with microtubules we expressed several 6myc-tagged MAP1a fragments in P19 EC and HeLa cells. Confocal immunofluorescence microscopy showed that the fragment consisting of amino acids (aa) 1-281 of MAP1a did not bind while the fragment consisting of aa 1-630 did, indicating that the region of MAP1a between aa 281 and 630 contains a microtubule-binding domain. Deletion of the basic repeats from aa 336-540 did not result in loss of microtubule binding, suggesting that the regions flanking the basic repeats can bind MAP1a to microtubules.

Selective loss of mouse embryos due to the expression of transgenic major histocompatibility class I molecules early in embryogenesis.

Among the numerous hypotheses proposed to explain the absence of fetal rejection by the mother in mammals, it has been suggested that regulation of expression of the polymorphic major histocompatibility complex (MHC) at the fetal-maternal interface plays a major role. In addition to a lack of MHC gene expression in the placenta throughout gestation, the absence of polymorphic MHC molecules on the early embryo, as well as their low level of expression after midgestation, could contribute to this important biologic phenomenon. In order to test this hypothesis, we have produced transgenic mice able to express polymorphic MHC class I molecules early in embryogenesis.

Identification of a new exon of the brain microtubule-associated protein 2.

The 5'-region of the transcripts encoding the HMW-(MAP2b) and LMW-(MAP2c) microtubule associated proteins in the brain was amplified by RT-PCR. The sequencing of cloned PCR fragments allowed to identify a new variant of brain HMW-MAP2 which contained, compared to MAP2b, an insertion of 246 bp located downstream the 5'-junction between MAP2b and MAP2c and that does not alter the open reading frame of MAP2b. The number of amino acid residues encoded by this insertion increases the molecular weight by 8.